HRT ‘potentially important’ in reducing women’s dementia risk Research suggests hormone replacement therapy may reduce risk of Alzheimer’s in some women The Guardian - UK · Jan 14, 2023
What the FDA's accelerated approval of a new Alzheimer's drug could mean for those with the disease – 5 questions answered about lecanemab The U.S. Food and Drug Administration approved the medication lecanemab, sold under the brand name Leqembi, on Jan. 6, 2023, through an “accelerated approval pathway” that fast-tracks promising clinical treatments for diseases in which there are no other currently effective options. The Conversation · Jan 13, 2023
Mayo Clinic expert provides perspective on FDA approval of another experimental Alzheimer's drug The Food and Drug Administration granted accelerated approval of a disease-modifying treatment that could potentially give some patients with Alzheimer's disease something they haven't had before: a medication that may slow the decline of memory and thinking. Tribune News Service · Jan 10, 2023
New Biomarker Test Can Identify Alzheimer's Neurodegeneration In Blood: Study A team of neuroscientists led by a University of Pittsburgh School of Medicine researcher developed a blood test to detect a new marker of Alzheimer's disease neurodegeneration. Read on for details: Dynamite News · Dec 28, 2022
New blood test developed to detect signs of Alzheimer’s disease ‘A blood test is cheaper, safer and easier to administer, and it can improve clinical confidence in diagnosing Alzheimer’s’ The Independent UK · Dec 28, 2022
Traumatic Brain Injury, PTSD Associated With Alzheimer's: Research The medical profession has never before investigated the effects of traumatic brain injury (TBI), post-traumatic stress disorder (PTSD) and genetic risk factors in a sizable cohort. Read on for details: Dynamite News · Dec 26, 2022
Researchers find signs of Alzheimer's disease in dolphins Researchers in Scotland have found dolphins with classic markers of Alzheimer's disease in their brains, potentially pointing to the reason the animals became stranded. ABC News · Dec 22, 2022
Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease On Nov. 30, Eisai and Biogen announced the results of their latest phase 3 clinical trial in Alzheimer’s disease. The verdict: an 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The study… The Conversation · Dec 21, 2022
Dolphins may suffer from Alzheimer’s disease, say researchers in Scotland Bottlenose dolphin, a long-finned pilot whale and a third species found to have markers of the degenerative disease The Guardian - UK · Dec 19, 2022
Stranded dolphins’ brains show common signs of Alzheimer’s disease – study The findings might help explain why some species get stranded, researchers say. The Independent UK · Dec 19, 2022
Dolphins may suffer brain damage similar to Alzheimer’s disease A new study shows four animals from different dolphin species have some of the brain changes associated with human Alzheimer’s disease The Independent UK · Dec 19, 2022
Why does the Alzheimer's brain become insulin-resistant? As the population ages, the number of people with neurodegenerative diseases, such as Alzheimer’s disease, increases. Approximately 75,000 Canadians are diagnosed with Alzheimer’s disease each year and experience a decline in their cognitive abilities. The ordeal usually lasts for several years while their family members watch helplessly. The Conversation · Dec 13, 2022
The first study to measure vitamin D in the brain could help reveal how to maintain cognitive health A new study found a link between higher concentrations of Vitamin D and improved cognition in aging people. Inverse · Dec 12, 2022
Commentary: By sharing their genetic risks, Hemsworth, Jolie are raising awareness of testing When actor Chris Hemsworth, aka Thor, God of Thunder, agreed to host a National Geographic series about extending the human life span, he didn’t expect to discover a genetic risk of his own. But that’s what happened as Hemsworth revealed on an episode of “Limitless” that he carries a common… Chicago Tribune · Dec 8, 2022
The Conversation · Dec 7, 2022 Harnessing the brain's immune cells to stave off Alzheimer's and other neurodegenerative diseases Many neurodegenerative diseases, or conditions that result from the loss of function or death of brain cells, remain largely untreatable. Most available treatments target just one of the multiple processes that can lead to neurodegeneration, which may not be effective in completely addressing disease symptoms or progress, if at all.
Wales Online · Dec 5, 2022 Blood test could detect Alzheimer's disease years before symptoms The new test could detect a toxic protein which has been linked to Alzheimer's disease years before any symptoms appear in the patient
The Independent UK · Dec 5, 2022 Blood test can detect ‘toxic’ protein years before Alzheimer’s symptoms – study Currently patients tend to receive a diagnosis of Alzheimer’s only after they show well-known signs of the disease.
Newcastle Herald · Dec 4, 2022 Trial offers new hope for Alzheimer's Disease treatment Hunter residents at high risk of developing Alzheimer's Disease will be given access to a clinical trial involving a breakthrough drug that appears to slow the development of the disease.
Wales Online · Nov 30, 2022 New drug is 'beginning of the end' of Alzheimer's - who will it help and when will it be available? Lecanemab has been shown in trials to slow the progress of early-stage Alzheimer's by 27%
The Independent UK · Nov 30, 2022 Exciting new drug is ‘beginning of the end’ for Alzheimer’s – so what is it and when could it be available? As trial results bring hope of an effective treatment, Lisa Salmon asks The Alzheimer’s Society what it means for people right now.
Manchester Evening News · Nov 30, 2022 Drug proven to slow decline in Alzheimer patients Lecanemab, a newly developed drug, has showed promising results in clinical trials among Alzheimer patients
The New Daily · Nov 30, 2022 ‘Momentous breakthrough’: New Alzheimer’s drug lives up to bold claims, with caveats Data supports claims that a new drug reduced cognitive and functional decline in Alzheimer's patients by 27 per cent in a clinical trial.
Daily Record · Nov 30, 2022 New Alzheimer's drug hailed as 'game-changing' as it's proven to slow disease The drug slowed the disease progression by 27 percent compared to patients taking the placebo.
Daily Mirror · Nov 30, 2022 Breakthrough Alzheimer's drug hailed as 'beginning of the end' for treating disease Lecanemab was found to have reduced memory decline by targeting and clearing amyloid, which is one of the proteins that build up in the brains of people with the disease
Wales Online · Nov 30, 2022 Simple urine test could be used to diagnose early-stage Alzheimer’s disease The early stage of the disease occurs before the irreversible dementia stage and is the golden window for intervention and treatment